The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
SYBRA is an open-label, phase 3, randomized controlled clinical trial that aims to assess the
use of synovial biopsies in predicting response to biologic therapy in patients with
rheumatoid arthritis that have failed disease-modifying drugs. The project has the potential
to help change the current practice by offering the best treatment option. The decision to
choose the best treatment for a particular patient is especially important in the context of
the growing number of therapies available as a first-line option and the lack of specific
biomarkers to predict response to treatment.